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Venous thromboembolism risk and prophylaxis
in the acute hospital care setting: report
from the ENDORSE study in Egypt
Hadi A Goubran1, Sherif Sholkamy2*, Alaa El-Haddad3, Alaa Mahmoud4ˆ, Mounir A Rizkallah5 and George Sobhy6
Abstract
Background: Venous thromboembolism (VTE) is a leading cause of hospital-related deaths worldwide. However,
the proportion of patients at risk of VTE who receive appropriate prophylaxis in Egypt is unknown. The ENDORSE
study in Egypt is part of a global initiative to uncover the incidence of high-risk surgical and medical patients and
determine what proportion of these patients receive appropriate VTE prophylaxis.
Methods: Ten Egyptian hospitals participated in this observational study, enrolling all surgical and medical patients
that met the study criteria. This resulted in a cohort of 1,008 patients in acute care facilities who underwent a
retrospective chart review. Each patient’s VTE risk status and the presence or absence of appropriate prophylactic
care was assessed according to the American College of Chest Physicians (ACCP) guidelines 2004.
Results: Of the 1,008 patients enrolled, 395 (39.2%) were found to be at high-risk for VTE. Overall, 227 surgical
patients were at high-risk, although only 80 (35.2%) received ACCP-recommended prophylaxis. Similarly, 55/268
(32.75%) of high-risk medical patients received appropriate VTE prophylaxis. Low molecular weight heparin was the
most commonly used anticoagulant, while mechanical prophylactic use was quite low (1.5%) in high-risk patients.
Conclusions: In Egypt, more than one-third of all patients hospitalized for surgery or acute medical conditions are
at high risk for developing VTE. However, only a small fraction of these patients receive appropriate VTE prophylaxis.
Corrective measures are necessary for preventing VTE morbidity and mortality in these high risk patients.
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Introduction
Venous thromboembolism (VTE) is a potential life-
threatening complication that can arise during
hospitalization for surgery or for medical illness. The
worldwide incidence of VTE is difficult to quantify, as
clinical symptoms can be non-specific and screening
techniques can fail to properly assess non-symptomatic
patients. Even so, it is thought that at least 5-15% of hos-
pitalized medical patients will develop VTE, making it
the most common preventable cause of in-hospital death
[1,2]. The conditions that predispose patients to
thromboembolism are well characterized and prophylac-
tic measures are effective in preventing VTE complica-
tion. Immobility, endothelial injury, certain drugs, and
various medical / surgical conditions (including blood
coagulation disorders, malignancy, stroke, and preg-
nancy) can all prompt VTE development [3]. Effective
prophylactic measures include treatment with anticoagu-
lant drugs and/or mechanical devices, such as elastic
graduated stockings or intermittent pneumatic compres-
sion. However, these measures can only be effective
when utilized properly in patients whose VTE risk has
been well-characterized.
There are a number of evidence-based guidelines for
assessment of VTE risk that are recognized internation-
ally. Assessment of VTE risk is done with Risk Assess-
ment Model (RAM). Physicians rely mainly on ACCP
guidelines, which define low, moderate, and high-risk
patients based on the type of surgery, mobility status,
and bleeding risk [4]. The ACCP defines high-risk
patients as those undergoing hip or knee fracture
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surgeries, or with major trauma, and those at high VTE
risk who also have a high bleeding risk. Patients that fall
into the high-risk group are estimated to have between
40-80% risk of developing VTE if no prophylaxis is pro-
vided [4]. Recommended prophylaxis measures include:
treatment with low molecular weight heparin (LMWH),
low-dose unfractionated heparin (UFH), or fondaparinux
for patients undergoing major surgery. Mechanical
methods of prophylaxis are urged for patients with a
high bleeding risk [4]. Unfortunately, numerous studies
suggest there is a disconnect between the current know-
ledge on VTE prevention and implementation of appro-
priate prophylactic measures, since many at-risk patients
do not receive prophylaxis and may not even be assessed
for VTE risk [5-7].
The need to improve VTE risk assessment and
prophylactic practices in the hospital setting is clear. For
this reason, the ENDORSE study was conducted in 32
countries in order to ascertain the scope of the VTE risk
management problem in the hospital setting [8]. The
primary goals of this initiative were to [1]: examine med-
ical and surgical patients in representative hospitals
worldwide who are at risk for VTE, and [2] determine
the percentage of at-risk patients who receive appropri-
ate prophylaxis. Secondly, we sought to define the num-
ber of patients at risk of VTE by various types of acute
illness and to elucidate the factors which determine
prophylaxis in the acute care setting. The aim of the
current publication is to present the country-specific
data from the Egyptian arm of the ENDORSE study. Ten
hospitals were chosen to participate, recruiting over
1,000 medical and surgical patients whose charts were
analyzed for VTE risk and the presence (or absence) of
prophylaxis. Our findings shed light on the scope of the
global health burden associated with VTE and highlight
how VTE risk is managed differently in different
countries.
Methods
Study design
The current analysis is part of a multi-center, observa-
tional study in 32 countries known as the ENDORSE
study (Epidemiological International Day for the Evalu-
ation of Patients at Risk for Venous Thromboembolism
in the Acute Hospital Care Setting) [8]. The goal of this
initiative were to [1] evaluate the risk of VTE among
medical and surgical patients in representative hospitals
worldwide and [2] to determine the percentage of at-risk
patients who receive appropriate prophylaxis. This pro-
gram was developed to test the hypotheses that use of
appropriate VTE prophylaxis varies by country and that
prophylaxis, even when implemented, may be used sub-
optimally. For the Egyptian arm of the ENDORSE study,
all eligible hospitals in the country were identified
(n = 80). Hospitals were considered eligible for enrol-
ment if they contained more than 50 beds, admitted
patients for the treatment of medical illnesses and
exacerbations of chronic diseases, and scheduled routine
major surgical procedures. Non-acute and single spe-
cialty hospitals were excluded. These hospitals were
chosen to be representative of the local practices and
standard of care in the country. Oversampling of hospi-
tals with known expertise in VTE was avoided. This
resulted in ten participating Egyptian hospitals, which
were responsible for identifying medical and surgical
patients who met the study criteria. Data was collected
directly from the patient medical charts by data abstrac-
tors, thus there was no influence on therapy and no
patient interaction. The study data was collected retro-
spectively in order to capture VTE risk, prophylaxis, and
bleeding risk occurring in the 14 days following patient
admission. The relevant medical information was col-
lected from eligible patients in consecutive order on the
day of the study and recorded in a case report form
(CRF). The survey was conducted in compliance with all
appropriate local and international ethical guidelines.
Patients
Study patients were selected in keeping with the
ENDORSE initiative as previously described [8]. Briefly,
medical and surgical patients were recruited for
ENDORSE participation during a single hospital stay
between November and December 2006 - . Surgical
patients who were at least 18 years of age and who met
the following criteria were included for study [1]: patient
underwent surgery that both required anesthesia and
lasted at least 45 minutes, and/or [2] patient had a major
traumatic injury that did not require a major operation.
Medical patients included in this study were over the
age of 40 and were admitted for treatment of a serious
acute medical illness. Patients admitted solely for diag-
nostic testing and those admitted to a floor not included
in the study (psychiatric, maternity, etc.) were excluded
from the study. In total, 1008 patients met these criteria,
including 478 surgical and 530 medical patients, and
were enrolled in the study.
Reported measures
The lead investigator at each hospital recorded the fol-
lowing information for each study site: number of beds,
approximate number of discharges per year, hospital
type (public/private/academic), availability of institu-
tional review boards, availability of wards, and the pres-
ence (or absence) of a hospital-wide DVT prevention
protocol. A patient enrollment log was maintained at
each hospital, which detailed relevant information about
the ward/floor in question. Eligible patients were
assigned a study identification number and their charts
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were reviewed for relevant medical information covering
their first 14 days in the hospital. A CRF was used to
record the patient data of interest: demographics, bio-
metric information, medical history, date of admission,
VTE risk factors, type/dose/frequency of prophylaxis,
presence/absence of therapeutic anticoagulation, and
discharge status. Prophylaxis was considered appropriate
if it met defined recommendations of the 2004 ACCP
guidelines [4]. Patients were considered to be at a sig-
nificant bleeding risk if they presented with or developed
intracranial hemorrhage, hepatic impairment, bleeding
at admission, active gastroduodenal ulcer, or known
bleeding disorder [9]. Patient and investigator data was
treated in compliance with all local applicable laws and
regulations. Appropriate measures were taken to safe-
guard data confidentiality.
Statistical analyses
Statistical analyses are discussed fully in the global
ENDORSE publication [8]. Quantitative data is pre-
sented as the median and the number of non-missing
data. Categorical data is given as the number and the
percentage of the population. Distribution of patients by
risk factor type and by prophylaxis is provided. Use of
VTE prophylaxis is presented as a function of key popu-
lation characteristics. The association between VTE
prophylaxis and risk factors is presented using logistic
regression models and odds ratios where appropriate. In
order to assess the true prevalence of VTE at 25% with a
precision of ±4%, a minimum of 450 patients per ana-
lysis group was utilized.
Results
The findings presented here are part of a larger, inter-
national, cross-sectional initiative known as the ENDORSE
study [8].
In each of the ten Egyptian hospitals that participated
in ENDORSE, a log of all medical and surgical patients
was generated (n = 1403), and patients were enrolled or
excluded based on the criteria outlined in Figure 1. This
resulted in a total of 1,008 eligible patients who were
selected to undergo a chart review. In our study popula-
tion, 478 (47.4%) of eligible persons were surgical
patients and 530 (52.6%) were medical patients. Of the
478 surgical patients, 227 (47.5%) were found to be at
high-risk of VTE, as were 168/530 (31.7%) medical
patients (Figure 2). This equates to 395/1008 (39.2%) of
the entire patient population meeting ACCP high-risk
criteria for VTE.
Patient characteristics and reasons for hospitalization
Characteristics of the high-risk patient population are
given in Table 1. There were more high-risk men
(n = 234) than women (n = 156) in our study group (60%
and 40%, respectively). The average age in the high-risk
surgical group was 52 years, while in the high-risk med-
ical group it was 59 years (Table 1). The reasons for pa-
tient hospital admittance are given in Table 2. Of
surgical patients with high VTE risk, the most common
surgery was hepatobiliary, with 33/227 (14.5%) of
patients undergoing this operation (Table 2). For the
high-risk medical group, the most common reasons for
admittance were cardiovascular disease (115/168, 68.5%)
followed by pulmonary infection (74/168, 44%) and
endocrine/metabolic disorders (43/168, 25.6%).
VTE risk factors in patient population
The VTE risk factors present before and during
hospitalization are provided in Table 3. Many high-risk
patients had conditions that put them at risk for VTE
prior to admission, such as chronic pulmonary disease
(54/395, 13.9%), obesity (25/395, 6.4%) and chronic heart
failure (23/395, 5.9%). Pulmonary infection and malig-
nancy were also common in these patients during their
hospitalization (Table 3). Admission to ICU/CCU oc-
curred in 108/395 (27.3%) high-risk patients (Table 3).
Additionally, a significant proportion (75/395, 19.0%) of
high-risk patients underwent complete immobilization,
and another 44 (11.1%) were immobile with bathroom
privileges.
Of the 395 patients at high-risk for VTE, 50 (12.7%)
had risk factors for bleeding and thus were considered
to have a contraindication to pharmacological prophy-
laxis. The most common bleeding risk factors differed
between the surgical and medical patient groups
(Table 4). For example, surgical patients were more likely
to have taken non-aspirin non-steroidal anti-inflammatory
drugs upon admission (10.1%), while medical patients were
more likely to have taken aspirin (20.8%) or exhibited sig-
nificant renal impairment (13.1%).
Proportions and types of VTE prophylaxis
We found that 39.2% (395/1008) of all patients included
in the study were considered to be at high risk of VTE.
Of these, only 34.2% (135/395) received ACCP-
recommended prophylaxis. Of the 227 surgical patients
with VTE risk, 80 (35.2%) received ACCP-recommended
prophylaxis, although a slightly higher proportion, 86/
227 (37.9%), received any type of prophylaxis (Figure 2).
Similarly, 63/268 (37.5%) of high-risk medical patients
received any kind of prophylaxis, with 55 (32.7%) receiv-
ing anticoagulant prophylaxis that met ACCP recom-
mendations. A small percentage (11.5% of surgical and
14.3% of medical patients) had contraindications to anti-
coagulant prophylaxis (Figure 2).
Interestingly, the proportion of patients receiving
prophylaxis appears to depend on their reason for ad-
mittance (Table 5). For example 100% of surgical
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1854 hospital beds assessed* 
1403 patients in eligible wards†
1008 assessable patients 
478 (47.4%) patients in surgical wards‡ 
44 empty beds in eligible wards 
407 beds in ineligible wards 
1447 beds in eligible wards 
Reasons for exclusion: 
44 missing hospital charts 
256 patients too young 
14 admitted for treatment of VTE 
3 admitted for diagnostic testing  
(ward not specified) 
6 minor operations (ward not specified) 
53 patients should be in excluded wards 
19 missing essential data 
530 (52.6%) patients in medical wards§
Figure 1 Selection of study population and reasons for exclusion. Abbreviations: VTE = venous thromboembolism * On basis of hospital
enrolment forms † On basis of patient enrolment logs, includes patients who did not meet protocol requirements (eg., age, type of condition, or
missing hospital chart) { Includes patients in general surgical units, surgical intensive care units, neurosurgery, gynecology and orthopedics }
Includes patients in other eligible wards.
All patients at VTE risk 
395 (39.2%) 
Any VTE prophylaxis 
63 (37.5%) 
-any anticoagulant: 59 (93.7%) 
-IPC without anticoagulant: 0 (0.0%) 
-GCS without anticoagulant: 1 (1.6%) 
ACCP recommended prophylaxis 
55 (32.7%) 
-ACCP anticoagulant: 55 (100.0%) 
-ACCP IPC without anticoagulant: 0 (0.0%) 
-ACCP GCS without anticoagulant: 0 (0.0%) 
Contraindications to anticoagulant prophylaxis* 
24 (14.3%) 
ACCP recommended 
prophylaxis 
135 (34.2%)
Surgical patients at VTE risk 
227 (47.5%) 
Medical patients at VTE risk 
168 (31.7%) 
Any VTE prophylaxis 
86 (37.9%) 
-any anticoagulant: 81 (94.2%) 
-IPC without anticoagulant: 0 (0.0%) 
-GCS without anticoagulant: 4 (4.7%) 
ACCP recommended prophylaxis 
80 (35.2%) 
-ACCP anticoagulant: 78 (97.5%) 
-ACCP IPC without anticoagulant: 0 (0.0%) 
-ACCP GCS without anticoagulant: 2 (2.5%) 
Contraindications to anticoagulant prophylaxis* 
26 (11.5%) 
Figure 2 Flowchart of high-risk patients: medical and surgical. Abbreviations: IPC = intermittent pneumatic compression, GCS= graduated
compression stockings, ACCP=American College of Chest Physicians-2004 Recommendations. * Risk factors for bleeding that were used to define
"contraindications to anticoagulant prophylaxis" include any of the following conditions present at current admission: - Intracranial hemorrhage -
Hepatic impairment (clinically relevant) - Bleeding at hospital admission (exclude if anticoagulant started after any type of surgery) - Active gastro-
duodenal ulcer (exclude if anticoagulant started after gastric/colon/small bowel surgery) - Known bleeding disorders (congenital or acquired).
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patients presenting with hip fractures or for rectosig-
moid surgery were given thromboprophylaxis, while only
21.2% of patients undergoing hepatobiliary surgery
received any prophylactic measure. Similar variability is
seen among the medical patients, although no group
reached 100% prophylaxis (Table 5). The medical
patients most likely to undergo prophylaxis were ische-
mic stroke patients, with 63.2% receiving ACCP-
recommended prophylaxis, respectively. In contrast, only
16.7% of acute non-infectious respiratory disease
patients received VTE prophylaxis of any kind.
The most common type of prophylaxis administered
was treatment with an ACCP-recommended anticoagu-
lant, which was given to 78 surgical and 55 medical
patients (Table 5). Of these, LMWH was most com-
monly prescribed, with 32.6% of high-risk surgical and
28.6% of high-risk medical patients receiving this form
of prophylaxis. Use of UFH, vitamin K-agonists, and
other anticoagulants were much less common (Table 6).
Very few at-risk patients were given mechanical prophy-
laxis. Graduated compression stockings (GCS) were used
for only one medical and five surgical patients. No high-
risk patients received intermittent pneumatic compres-
sion (IPC) or foot pump treatments in the absence of
anticoagulant therapy.
Discussion
Egyptian patients enrolled in Endorse exhibit nearly the
same features as compared to the global study. First, in
both the global and Egyptian studies, surgical patients
make up a slightly higher percentage of high-risk
patients than do medical patients. Second, risk factors
for bleeding present at the time of admission were simi-
lar in both studies, with aspirin consumption being the
most common in both cohorts. Third, the Egyptian co-
hort exhibited many trends in prophylactic usage that
were seen in the global report. In both global and Egyp-
tian patient groups, the majority of those given
prophylaxis received thromboprophylaxis that met
ACCP guidelines. On both the international and Egypt-
specific levels, there was substantial room for improve-
ment to achieve a goal of 100% prophylaxis compliance,
as only ~30-50% of high-risk patients received any pre-
ventative care. The most common class of anticoagulant
Table 1 Characteristics of high-risk patients
Patient characteristics Surgical risk Medical risk All risk
(N= 227) (N= 168) (N= 395)
Male, n/N (%) 136/225
(60.4%)
98/165
(59.4%)
234/390
(60.0%)
Age in years, median 52.0 59.0 55.0
Weight in kg, median 80.0 73.5 80.0
Height in cm, median 167.5 160.0 165.0
BMI in kg/m2 median 26.1 25.8 26.0
Length of hospitalization in
days up to survey date, median
7.0 4.0 5.0
Abbreviations: BMI = body mass index.
Note: n is the numerator used in calculating the percentage; denominators
may vary due to missing data.
Table 2 Reasons for hospital admission for high-risk
patients
Reasons for hospital
admission
Surgical risk Medical risk All risk
(N= 227) (N = 168) (N = 395)
Medical Conditions
Acute heart failure
(NYHA Class III or IV)
0 (0.0%) 30 (17.9%) 30 (7.6%)
Ischemic stroke 1 (0.4%) 19 (11.3%) 20 (5.1%)
Hemorrhagic stroke 1 (0.4%) 3 (1.8%) 4 (1.0%)
Other cardiovascular disease 26 (11.5%) 63 (37.5%) 89 (22.5%)
Hematologic disease 8 (3.5%) 7 (4.2%) 15 (3.8%)
Acute non-infectious
respiratory disease
3 (1.3%) 24 (14.3%) 27 (6.8%)
Pulmonary infection 13 (5.7%) 74 (44.0%) 87 (22.0%)
Malignancy (active) 66 (29.1%) 14 (8.3%) 80 (20.3%)
Infection (non-respiratory) 24 (10.6%) 12 (7.1%) 36 (9.0%)
Rheumatologic or
inflammatory
0 (0.0%) 4 (2.4%) 4 (1.0%)
Neurologic 0 (0.0%) 8 (4.8%) 8 (2.0%)
Renal 10 (4.4%) 20 (11.9%) 30 (7.6%)
Endocrine/Metabolic 35 (15.4%) 43 (25.6%) 78 (19.7%)
GI/Hepatobiliary 48 (21.1%) 24 (14.3%) 72 (18.2%)
Other medical condition 23 (10.1%) 4 (2.0%) 27 (6.8%)
Type of 1st Major Operation
Hip replacement 0 (0.0%) N/A N/A
Knee replacement 2 (0.9%) N/A N/A
Hip fracture 6 (2.6%) N/A N/A
Curative arthroscopy 1 (0.4%) N/A N/A
Other ortho trauma 23 (10.1%) N/A N/A
Colon/Small bowel 19 (8.4%) N/A N/A
Rectosigmoid 4 (1.8%) N/A N/A
Gastric 8 (3.5%) N/A N/A
Hepatobiliary 33 (14.5%) N/A N/A
Urologic 19 (8.4%) N/A N/A
Vascular 11 (4.8%) N/A N/A
Thoracic 4 (1.8%) N/A N/A
Gynecologic 10 (4.4%) N/A N/A
Other major surgery 78 (34.4%) N/A N/A
Admitted with major trauma
but surgery not performed
9 (4.0%) N/A N/A
Abbreviations: NYHA=New York Heart Association, GI = gastrointestinal.
Note: n is the numerator used in calculating the percentage; denominators
may vary due to missing data.
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given to patients globally and Egyptian patients specific-
ally, were LMWH to ~30%-40%. Finally, in both studies,
surgical patients were more likely to receive heparin
prophylaxis than medical patients. This is consistent
with other research, which found that VTE prophylaxis
is less often provided to medical patients than surgical
patients, despite a similar risk [10].
There were however some important differences be-
tween the Egyptian and global patient population ana-
lyzed in this initiative. In the global study, 51.8% of all
patients were found to be at high-risk for VTE, com-
pared to only 39.2% of Egyptian patients. One reason
that the Egyptian arm of this study identified fewer at-
risk patients than the global cohort may be related to
the demographics of the Egyptian group. In the Egyptian
study, there was a 60% to 40% split of men to women,
whereas the genders were more equally represented in
the global cohort. The Egyptian study population was
also ten years younger, on average, than the global pa-
tient group (55 years vs. 65 years of age, respectively).
This may have had a significant impact on the overall
VTE risk rate, as incidence of VTE has been shown to
increase with age in numerous studies [3]. Additionally,
the Egyptian group exhibited lower incidences of obesity
and of various other medical conditions (such as chronic
heart failure, pulmonary infection, and rheumatologic,
inflammatory, neurologic, and metabolic diseases) than
the global cohort. Finally, Egyptian patients seemed to
have fewer bleeding risk factors overall during their hos-
pital stay, with much lower rates of central venous
catheterization and mechanical ventilation. The combin-
ation of all of these factors may account for the lower
risk of VTE in the Egyptian cohort.
Although the Egyptian cohort had a lower overall rate of
high-risk patients, we found that a much lower percentage
of such at-risk cases received appropriate prophylaxis
compared to the global survey. In the Egyptian hospitals
sampled, only 34.2% of those at high VTE risk received
ACCP-recommended prophylaxis, while globally, appro-
priate prophylaxis was given to 50.2%. The rate of prophy-
lactic usage in Egypt is comparable to the rates in Greece,
Pakistan, and the United Arab Emirates, ranging between
the lowest (3%, Bangladesh) and highest (70%, Germany)
rates of prophylaxis globally [8]. Of course, there still
remains great room for improvement in all instances, with
the potential for enormous benefits if 100% compliance
could be achieved. The reasons behind such modest rates
of VTE prophylaxis are likely to be numerous and highly
Table 3 VTE risk factors prior to and during patient
hospitalization
VTE risk factors Surgical risk Medical risk All risk
(N= 227) (N= 168) (N= 395)
Conditions Present Prior to
Hospital Admission
Previous
venous thromboembolism
6 (2.7%) 1 (0.6%) 7 (1.8%)
Thrombophilia (laboratory
documented)
0 (0.0%) 0 (0.0%) 0 (0.0%)
Varicose veins or venous
insufficiency
13 (5.9%) 5 (3.0%) 18 (4.6%)
Post-menopausal hormone
replacement therapy
2 (0.9%) 0 (0.0%) 2 (0.5%)
Chronic pulmonary disease 22 (10.0%) 32 (19.0%) 54 (13.9%)
Long term immobility 5 (2.3%) 5 (3.0%) 10 (2.6%)
Pregnancy
(within 3 months)
1 (0.5%) 0 (0.0%) 1 (0.3%)
Obese (based on
physician's note)
16 (7.3%) 9 (5.4%) 25 (6.4%)
Contraceptives 2 (0.9%) 1 (0.6%) 3 (0.8%)
Chronic heart failure 0 (0.0%) 23 (13.7%) 23 (5.9%)
Risk Factors for VTE During
Hospital Admission
Admitted to ICU/CCU 37 (16.3%) 71 (42.3%) 108 (27.3%)
Central venous catheter 22 (9.7%) 14 (8.3%) 36 (9.1%)
Mechanical ventilation 4 (1.8%) 9 (5.4%) 13 (3.3%)
Immobile with
bathroom privileges
19 (8.4%) 25 (14.9%) 44 (11.1%)
Complete immobilization 36 (15.9%) 39 (23.2%) 75 (19.0%)
Cancer therapy 2 (0.9%) 9 (5.4%) 11 (2.8%)
Heparin induced
thrombocytopenia
0 (0.0%) 0 (0.0%) 0 (0.0%)
Abbreviations: VTE = venous thromboembolism, ICU= intensive care unit,
CCU= cardiac care unit.
Note: n is the numerator used in calculating the percentage; denominators
may vary due to missing data.
Table 4 Incidence of bleeding risk and contraindications
to anticoagulant therapies
Risk factors for bleeding
present at current admission
Surgical risk Medical risk All risk
(N= 227) (N= 168) (N = 395)
Significant renal impairment 6 (2.6%) 22 (13.1%) 28 (7.1%)
Intracranial hemorrhage 0 (0.0%) 1 (0.6%) 1 (0.3%)
Low platelet count
(<100,000 per μl)
6 (2.6%) 10 (6.0%) 16 (4.1%)
Known bleeding disorder
(congenital or acquired)
1 (0.4%) 3 (1.8%) 4 (1.0%)
Hepatic impairment
(clinically relevant)
7 (3.1%) 16 (9.5%) 23 (5.8%)
Bleeding at hospital admission 19 (8.4%) 3 (1.8%) 22 (5.6%)
Active gastroduodenal ulcer 2 (0.9%) 4 (2.4%) 6 (1.5%)
Aspirin on admission 12 (5.3%) 35 (20.8%) 47 (11.9%)
NSAID on admission
(excluding aspirin)
23 (10.1%) 10 (6.0%) 33 (8.4%)
Abbreviations: NSAID = non-steroidal anti-inflammatory drug.
Note: n is the numerator used in calculating the percentage; denominators
may vary due to missing data.
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dependent on the specifics of medical practices in various
countries; thus further examination on a hospital-specific
level is needed.
While surgical patients were more likely to receive
prophylaxis in the global study, near equal rates of
prophylactic use was observed for both the Egyptian
surgical and medical groups. This equality in prophylac-
tic use between the two groups may be due to the fact that
prophylactic utilization was low overall in Egypt, regardless
of what type of medical condition/procedure was being
addressed. Those undergoing most types of surgery (includ-
ing knee-replacements, bowel, gastric, hepatobiliary,
Table 5 Rates and types of VTE prophylaxis based on diagnosis
Type of diagnosis Any Px
received N
Any
anticoagula
GCS w/o
anticoagulant/IPC
ACCP Px
received
ACCP
anticoagulant
ACCP GCS w/o
anticoagulant/IPC
(%) ntn (%)* n (%)* N (%) n (%)* n (%)*
Surgical Patients at VTE Risk
Hip replacement 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Knee replacement 1 (50.0%) 1 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Hip fracture 6 (100.0%) 6 (100.0%) 0 (0.0%) 6 (100.0%) 6 (100.0%) 0 (0.0%)
Curative arthroscopy 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Other ortho trauma 13 (56.5%) 13 (100.0%) 0 (0.0%) 11 (47.8%) 11 (100.0%) 0 (0.0%)
Colon/small bowel 8 (42.1%) 8 (100.0%) 0 (0.0%) 8 (42.1%) 8 (100.0%) 0 (0.0%)
Rectosigmoid 4 (100.0%) 3 (75.0%) 1 (25.0%) 3 (75.0%) 3 (100.0%) 0 (0.0%)
Gastric 4 (50.0%) 4 (100.0%) 0 (0.0%) 4 (50.0%) 4 (100.0%) 0 (0.0%)
Hepatobiliary 7 (21.2%) 6 (85.7%) 1 (14.3%) 7 (21.2%) 6 (85.7%) 1 (14.3%)
Urologic 5 (26.3%) 5 (100.0%) 0 (0.0%) 5 (26.3%) 5 (100.0%) 0 (0.0%)
Vascular 6 (54.5%) 5 (83.3%) 1 (16.7%) 6 (54.5%) 5 (83.3%) 1 (16.7%)
Thoracic 2 (50.0%) 2 (100.0%) 0 (0.0%) 2 (50.0%) 2 (100.0%) 0 (0.0%)
Gynecologic 5 (50.0%) 5 (100.0%) 0 (0.0%) 5 (50.0%) 5 (100.0%) 0 (0.0%)
Other surgery 22 (28.2%) 20 (90.9%) 1 (4.5%) 20 (25.6%) 20 (100.0%) 0 (0.0%)
Major trauma but surgery not performed 3 (33.3%) 3 (100.0%) 0 (0.0%) 3 (33.3%) 3 (100.0%) 0 (0.0%)
Medical Patients at VTE Risk
Acute heart failure (NYHA Class III or IV) 12 (40.0%) 11 (91.7%) 0 (0.0%) 9 (30.0%) 9 (100.0%) 0 (0.0%)
Ischemic stroke 12 (63.2%) 12 (100.0%) 0 (0.0%) 12 (63.2%) 12 (100.0%) 0 (0.0%)
Hemorrhagic stroke 2 (66.7%) 2 (100.0%) 0 (0.0%) 2 (66.7%) 2 (100.0%) 0 (0.0%)
Other cardiovascular disease 36 (57.1%) 34 (94.4%) 0 (0.0%) 32 (50.8%) 32 (100.0%) 0 (0.0%)
Hematologic disease 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Malignancy (active) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Acute non-infectious respiratory disease 4 (16.7%) 3 (75.0%) 1 (25.0%) 3 (12.5%) 3 (100.0%) 0 (0.0%)
Pulmonary infection 22 (29.7%) 20 (90.9%) 0 (0.0%) 20 (27.0%) 20 (100.0%) 0 (0.0%)
Infection (non-respiratory) 3 (25.0%) 3 (100.0%) 0 (0.0%) 2 (16.7%) 2 (100.0%) 0 (0.0%)
Rheumatotologic/Inflammatory 1 (25.0%) 1 (100.0%) 0 (0.0%) 1 (25.0%) 1 (100.0%) 0 (0.0%)
Neurologic 3 (37.5%) 3 (100.0%) 0 (0.0%) 3 (37.5%) 3 (100.0%) 0 (0.0%)
Renal 7 (35.0%) 7 (100.0%) 0 (0.0%) 7 (35.0%) 7 (100.0%) 0 (0.0%)
Endocrine/Metabolic 19 (44.2%) 17 (89.5%) 0 (0.0%) 17 (39.5%) 17 (100.0%) 0 (0.0%)
GI/Hepatobiliary 5 (20.8%) 5 (100.0%) 0 (0.0%) 5 (20.8%) 5 (100.0%) 0 (0.0%)
Other medical condition 2 (50.0%) 2 (100.0%) 0 (0.0%) 2 (50.0%) 2 (100.0%) 0 (0.0%)
Abbreviations: VTE = venous thromboembolism, Px = prophylaxis, IPC = intermittent pneumatic compression, GCS = graduted compression stockings, w/o =without,
ACCP =American College of Chest Physicians, NYHA=New York Heart Association, GI = gastrointestinal* The denominator is patients who received prophylaxis
IPC without Anticoagulation n = 0.
ACCP IPC w/o Anticoagulant n = 0.
Goubran et al. Thrombosis Journal 2012, 10:20 Page 7 of 9
http://www.thrombosisjournal.com/content/10/1/20
urologic, vascular, thoracic, and gynecological) had prophy-
laxis rates substantially lower than in the global study. A
similar trend was seen in the majority of Egyptian medical
patients, with low rates of prophylaxis independent of the
reason for hospitalization. We also recorded very low rates
of mechanical prophylaxis in Egypt, with no high-risk
patients receiving IPC or AVI and only 1.5% receiving GCS.
This finding was not surprising, as other international stud-
ies also have reported low rates of IPC mechanical prophy-
laxis outside of the United States [11].
This study had a number of limitations that are im-
portant to consider. Mainly, the findings are based on
patients receiving care in 10 hospitals, which represents
~12.5% of all of the hospitals in Egypt. While the
country-wide rates of VTE prophylaxis may differ, the
low number of high-risk patients whose VTE needs are
being addressed in this study suggests there is an imme-
diate need to improve VTE risk management in Egypt.
Additionally, the study data only represents the first
14 days of medical care after admission, thus our find-
ings may underestimate the true incidence of VTE.
Literature comparing rates of potentially-life threaten-
ing but preventable complications of hospitalization
between Egypt and other areas of the world is scarce.
Thus another limitation of our study is the lack of com-
parable data to aid in the interpretation of these
observed trends. A recent study comparing coronary
surgery in Egypt and Germany found that Egyptian
patients had much higher incidence of hospital-related
mortality compared to their western counterparts (6.1%
vs. 1.7%, respectively) [12]. Another study of Egyptian
patients with cerebral venous thrombosis revealed that
only 67% received therapeutic anticoagulant treatment,
compared to 85% of patients in an international cohort
[13]. That study also found higher rates of morbidity
and mortality after the thrombotic event in Egypt com-
pared to other countries (51% vs. 19%), though the
authors suggest this may be attributable, in part, to more
severe disease at presentation [13].
Thus, we have reason to believe that our findings are
consistent with the trends seen in other hospital-based
surveys of Egyptian patient care.
As a leading cause of hospital-related, preventable
morbidity and mortality, VTE contributes significantly to
health burden around the world. The data presented
here reveal that, like many other countries surveyed,
VTE risk assessment and prophylaxis is underutilized in
the Egyptian acute care setting. In order to raise the
rates of appropriate prophylaxis towards a goal of 100%
implementation in an effective manner, we must under-
stand why so many high-risk patients fail to get the
prophylactic measures they need. Education aimed at
increasing VTE awareness in medical care providers, as
well as implementation of VTE risk assessment and
prophylaxis protocols in every hospital, is immediately
necessary to address this widespread problem.
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